Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL) of New Delhi, India, announced that RLL received approval from the U. zithromax. S. Food and Drug Administration (FDA) to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets. The Division of Bioequivalence determined that the tablets are the bioequivalent of the branded drug Claritin-D 24-Hour Extended Relief Tablets made by the Schering Corp., sales of which were $64.5 million over the last year.
Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
Eight Major Job Trends For 2008
Today’s Best Part-Time Jobs
Five Ways To Successfully Negotiate A Salary
Loratadine and Pseudoephedrine Sulfate Extended Relief …
Read the rest of this article with a Free Trial at HighBeam Research.